Skip to content
The Nexus
HEALTHJul 15 · 08:30 UTCSTAT NEWSLizzy Lawrence

STAT+: Under a new leader, the FDA’s biologics center moves to steady itself after stormy chapter

Karim Mikhail, acting director of the FDA’s Center for Biologics Evaluation and Research, addressed staff to emphasize his connection to their experiences, following the unconventional leadership of his predecessor Vinay Prasad. The center is working to stabilize after a period described as 'stormy.'

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Karim MikhailpersonVinay PrasadpersonFDA’s Center for Biologics Evaluation and ResearchorganizationFood and Drug AdministrationorganizationSTAT+organization
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting

STAT+: Under a new leader, the FDA’s biologics center moves to steady itself after stormy chapter · The Nexus